
Chiesi Global Rare Diseases Announces Approval of FERRIPROX™ MR Deferiprone Extended-Release Tablets in Canada
New formulation allows twice-daily dosing in patients with transfusional iron overload due to thalassemia syndromes when current chelation therapy is inadequate, or sickle cell disease or other anemias. BOSTON, March 31, 2023 /PRNewswire/ — Chiesi Global Rare Diseases, a business unit of… Click here to view original post… […]